US Patent

US8546399 — Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases

Composition of Matter · Assigned to AbbVie Inc · Expires 2031-06-27 · 5y remaining

Vulnerability score 10/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that inhibit anti-apoptotic Bcl-2 proteins and their use in treating diseases where these proteins are expressed.

USPTO Abstract

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Drugs covered by this patent

Patent Metadata

Patent number
US8546399
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-06-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.